In the midst of increased regulatory scrutiny involving erythropoiesis-stimulating agents (ESAs), Affymax Inc. is forging ahead with a Phase III program of its anemia drug, Hematide, in chronic renal failure patients. (BioWorld Today)
In the midst of increased regulatory scrutiny involving erythropoiesis-stimulating agents (ESAs), Affymax Inc. is forging ahead with a Phase III program of its anemia drug, Hematide, in chronic renal failure patients. (BioWorld Today)
Five years after Tercica Inc. first acquired rights to Genentech Inc.'s insulin-like growth factor-1 (IGF-1) - for which it gained approval as Increlex in 2005 for short stature in children with primary IGF-1 deficiency - the two companies expanded their collaboration to develop combination IGF-1 and growth hormone products for idiopathic short stature and adult growth hormone deficiency.(BioWorld Today)
Five years after Tercica Inc. first acquired rights to Genentech Inc.'s insulin-like growth factor-1 (IGF-1) - for which it gained approval as Increlex in 2005 for short stature in children with primary IGF-1 deficiency - the two companies expanded their collaboration to develop combination IGF-1 and growth hormone products for idiopathic short stature and adult growth hormone deficiency.(BioWorld Today)
In its largest deal to date, RNAi firm Silence Therapeutics plc is partnering with AstraZeneca plc in a potential £200 million (US$400 million) to develop drugs against respiratory disease targets. (BioWorld International)
In its largest deal to date, RNAi firm Silence Therapeutics plc is partnering with AstraZeneca plc in a potential £200 million (US$400 million) to develop drugs against respiratory disease targets. (BioWorld International)
